



PRODUCT: **Entresto® (sacubitril/valsartan)**

COMPANY: Novartis Pharmaceuticals Corporation

THERAPEUTIC AREA & INDICATION:

Reduce hospitalizations and deaths in adults with chronic heart failure through improvement in the heart's ability to pump blood to the body

ABOUT THE PRODUCT

Entresto® is a first-in-class ARNI* and first breakthrough in Heart Failure (HF) treatment in over a decade. Novartis researchers reimaged medicine by combining a neprilysin inhibitor (sacubitril) with an angiotensin receptor blocker (valsartan) to create Entresto®. By 2030, 1 in 33 individuals will have HF. Patients with HF have a 50% risk of death within 5 years of disease onset. Entresto® was developed with the goal of improving patients' lives by reducing HF hospitalization and mortality. Patients treated with Entresto® are less likely to be hospitalized and incur lower total healthcare costs versus those treated with ACEis** a standard of care. Company's literature for the application for the Prix Galien USA 2021. Please refer to complete submission package for references.

*Angiotensin Receptor-Nepriylsin inhibitor (ARNI).

**Angiotensin Converting enzyme inhibitor (ACEi) For side effect information, please refer to the company website: <https://www.novartis.us/sites/www.novartis.us/files/entresto.pdf>